Population
230 patients from 71 families with a documented hereditary deficiency of a natural coagulation inhibitor
Design
Cohort
Authors
Loading...
High thrombosis risk in hereditary deficiencies may inform anticoagulation decisions after first event; leaves open randomized confirmation of benefit.
Patients with hereditary AT-III, PC, or PS deficiency have an 80% to 90% lifetime risk of thrombosis and a 63% recurrence rate, supporting the use of long-term oral anticoagulation after a first event.
Pabinger et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: